Article Figures & Data
Tables
- TABLE 1
Elimination of antituberculosis drugs and their effects on enzyme and transporter activitya
↵a —, either unknown or no well-established effect. ABC, ATP-binding cassette transporters; CYP, cytochrome 450; OATP, organic-anion-transporting polypeptide; BCRP, breast cancer resistance protein; MRP1, multidrug resistance-associated protein 1; P-gp, P-glycoprotein; PAS, p-aminosalicylic acid; SLC, solute carrier family; UGT, uridine 5′-diphospho-glucuronosyltransferase.
- TABLE 2
Elimination of DAAs for hepatitis C and their effects on enzymes and transporters activitya
↵a —, either unknown or no well-established effect. BCRP, breast cancer resistance protein; CYP, cytochrome 450; DAAs, direct-acting antiviral; OATP, organic-anion-transporting polypeptide; P-gp, P-glycoprotein; UGT, uridine 5′-diphospho-glucuronosyltransferase.
- TABLE 3
Drug-drug interactions between drug-susceptible tuberculosis and hepatitis C drugsa
↵a *, as recommended in the AALSD/IDSA hepatitis C treatment guidelines; #, drugs put into drug-susceptible and drug-resistant categories based on where they are commonly utilized (overlap does exist); INH, isoniazid; RIF, rifampin; RFP, rifapentine; RFB, rifabutin; PZA, pyrazinamide; ETH, ethambutol; red, drugs that should not be coadminstered; orange, potential clinically significant interaction; yellow, potential weak interaction unlikely to be clinically significant; green, no clinically significant interaction expected.
- TABLE 4
Drug-drug interactions between drug-resistant tuberculosis and hepatitis C drugsa
↵a *, as recommended in the AALSD/IDSA hepatitis C treatment guidelines; #, drugs put into drug-susceptible and drug-resistant categories based on where they are commonly utilized (overlap does exist); LEVO, levofloxacin; MOXI, moxifloxacin; AMK, amikacin; KAN, kanamycin; CAP, capreomycin; LZD, linezolid; CFZ, clofazimine; PAS, para-aminosalicylic acid; CS, cycloserine; ETN, ethionamide; BDQ, bedaquiline; DEL, delamanid; orange, potential clinically significant interaction; yellow, potential weak interaction unlikely to be clinically significant; green, no clinically significant interaction expected. Genotypes for first-line treatment with elbasvir and grazoprevir, see reference 94.
- TABLE 5
Characteristics of anti-tuberculosis drugs related to liver disease
↵a Although levofloxacin and moxifloxacin were associated with increased risk of acute liver injury compared to clarithromycin (100), they are generally not considered hepatotoxic drugs.
